{"id":9170,"date":"2025-11-11T10:47:01","date_gmt":"2025-11-11T07:47:01","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9170"},"modified":"2025-11-11T10:47:01","modified_gmt":"2025-11-11T07:47:01","slug":"additional-clinical-perspectives-and-key-additions-2025-acc-aha-hypertension-guidelines","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/additional-clinical-perspectives-and-key-additions-2025-acc-aha-hypertension-guidelines\/","title":{"rendered":"Additional Clinical Perspectives and Key Additions \u2013 2025 ACC\/AHA Hypertension Guidelines"},"content":{"rendered":"
Additional Clinical Perspectives and Key Additions \u2013 2025 ACC\/AHA Hypertension Guidelines<\/div>\n
<\/div>\n
Source: Supplementary Commentary: Published by the Jordanian Cardiac Society (JCS) on its official platforms at the time of the guideline release in August, based on the (ACC)& (AHA) Hypertension Guidelines, 2025.<\/div>\n
<\/div>\n
Date: November 2025<\/div>\n
Target Audience: Primary-care physicians, emergency physicians, internists, and cardiologists.<\/div>\n
<\/div>\n
Keynotes:<\/div>\n
1.\u2060 \u2060PREVENT Risk Calculator \u2013 Core Variables and Treatment Thresholds<\/div>\n
\u2022 The PREVENT score replaces the former scores for estimating cardiovascular risk.<\/span><\/div>\n
\u2022 Based on over 3 million contemporary adults (2008\u20132022), reflecting modern demographics and treatment patterns.<\/span><\/div>\n
\u2022 Calculates both 10-year and 30-year CVD risk.<\/span><\/div>\n
\u2022 Treatment in Stage 1 hypertension (130\u2013139 \/ 80\u201389 mm Hg) should be initiated if PREVENT 10-year risk \u2265 7.5 % or if comorbidities exist (diabetes, CKD, ASCVD).<\/span><\/div>\n
\u2022 Core variables included:<\/span><\/div>\n
1. Age, sex, race\/ethnicity<\/span><\/div>\n
2. Systolic and diastolic blood pressure<\/span><\/div>\n
3. Total cholesterol and HDL-cholesterol<\/span><\/div>\n
4. Diabetes status<\/span><\/div>\n
5. Smoking (tobacco use)<\/span><\/div>\n
6. Body-mass index (BMI)<\/span><\/div>\n
7. Chronic kidney disease (CKD)<\/span><\/div>\n
8. Education \/ social deprivation index<\/span><\/div>\n
9. Use of antihypertensive therapy<\/span><\/div>\n
10. Reproductive history (gestational hypertension or preterm birth in women)<\/span><\/div>\n
\u2022 Access link: https:\/\/professional.heart.org\/en\/guidelines-and-statements\/prevent-risk-calculator<\/span><\/div>\n
<\/div>\n
2.\u2060 \u2060Pregnancy and Post-Partum Hypertension<\/div>\n
\u2022 Initiate pharmacologic therapy when BP \u2265 140\/90 mm Hg.<\/span><\/div>\n
\u2022 Preferred agents: labetalol, extended-release nifedipine, or methyldopa.<\/span><\/div>\n
\u2022 Contraindicated: ACE inhibitors, ARBs, and direct renin inhibitors.<\/span><\/div>\n
\u2022 Target BP: Maintain < 140\/90 mm Hg; avoid excessive lowering (< 130 mm Hg) to prevent placental hypoperfusion.<\/span><\/div>\n
\u2022 Monitoring:<\/span><\/div>\n
\u2022 Measure BP within 72 h postpartum,<\/span><\/div>\n
\u2022 Repeat at 7\u201310 days, then 6\u201312 weeks.<\/span><\/div>\n
\u2022 Classification: Persistent hypertension beyond 12 weeks = chronic hypertension.<\/span><\/div>\n
\u2022 Long-term impact: Hypertensive disorders of pregnancy and pre-eclampsia are now major cardiovascular risk enhancers in the PREVENT model.<\/span><\/div>\n
<\/div>\n
3.\u2060 \u2060Central Nervous System (CNS) and Cerebrovascular Disease<\/div>\n
\u2022 Hypertension is the leading modifiable factor for stroke, intracerebral hemorrhage (ICH), and cognitive decline.<\/span><\/div>\n
<\/div>\n
A. Acute Ischemic Stroke<\/div>\n
1. Before thrombolysis\/thrombectomy: reduce BP < 185\/110 mm Hg.<\/span><\/div>\n
2. Without reperfusion therapy: treat only if SBP > 220 or DBP > 120 mm Hg.<\/span><\/div>\n
3. Post-reperfusion: maintain < 180\/105 mm Hg for 24 h.<\/span><\/div>\n
<\/div>\n
B. Intracerebral Hemorrhage (ICH)<\/div>\n
1. Lower systolic BP rapidly but safely to \u2248 140 mm Hg within 1 hour.<\/span><\/div>\n
2. Avoid reductions < 110 mm Hg.<\/span><\/div>\n
3. IV options: nicardipine, clevidipine, or labetalol.<\/span><\/div>\n
<\/div>\n
C. Long-Term Prevention<\/div>\n
\u2022 Maintain BP < 130\/80 mm Hg post-stroke or TIA.<\/span><\/div>\n
\u2022 Tight control reduces recurrence, cognitive decline, and dementia.<\/span><\/div>\n
<\/div>\n
4.\u2060 \u2060Additional Organ Protection and Screening<\/div>\n
\u2022 Urine albumin-to-creatinine ratio (UaCr): mandatory at diagnosis and follow-up.<\/span><\/div>\n
\u2022 Primary hyperaldosteronism: screen in resistant, early-onset, or severe hypertension.<\/span><\/div>\n
\u2022 Microvascular protection: include renal, retinal, and cerebral monitoring.<\/span><\/div>\n
\u2022 Cognitive health: sustained systolic < 130 mm Hg helps delay small-vessel disease.<\/span><\/div>\n
<\/div>\n
5.\u2060 \u2060Clinical Note \u2013 Immediate-Release Oral Nifedipine<\/div>\n
<\/div>\n
Immediate-release oral (Not SL)nifedipine may be used only in pregnancy-related severe hypertension (\u2265 160\/110 mm Hg) as a safe, rapid option when IV access is unavailable.<\/div>\n
<\/div>\n
Outside pregnancy, it should not be used for hypertensive emergencies and is rarely appropriate for urgencies; safer oral or IV agents (labetalol, captopril, clonidine, nicardipine) are preferred to avoid abrupt, harmful BP reductions.<\/div>\n
<\/div>\n
6.\u2060 \u2060Key Take-Home Points<\/div>\n
1. BP Target: < 130\/80 mm Hg for most adults; individualize for frail or pregnant patients.<\/span><\/div>\n
2. Risk Assessment: Use PREVENT score (\u2265 7.5 % = pharmacologic threshold).<\/span><\/div>\n
3. Pregnancy: Treat at 140\/90 mm Hg; avoid RAAS blockers; monitor postpartum.<\/span><\/div>\n
4. CNS:<\/span><\/div>\n
\u2022 Thrombolysis: < 185\/110 mm Hg<\/span><\/div>\n
\u2022 Intracerebral hemorrhage: \u2248 140 mm Hg<\/span><\/div>\n
\u2022 Long-term: < 130\/80 mm Hg<\/span><\/div>\n
5. Organ Protection: Routine UaCr, endocrine screening, cognitive follow-up.<\/span><\/div>\n
6. Lifestyle: Weight, diet, physical activity, and smoking cessation remain fundamental.<\/span><\/div>\n
<\/div>\n
Jordan Cardiac Society (JCS)<\/div>\n
\ud83c\udf10 www.jordan-cardiac.org<\/div>\n
\ud83d\udd17 http:\/\/jordaniancs.ecardroots.com<\/div>\n
Date: November 2025<\/div>\n","protected":false},"excerpt":{"rendered":"

Additional Clinical Perspectives and Key Additions \u2013 2025 ACC\/AHA Hypertension Guidelines Source: Supplementary Commentary: Published by the Jordanian Cardiac Society (JCS) on its official platforms at the time of the guideline release in August, based on the (ACC)& (AHA) Hypertension Guidelines, 2025. Date: November 2025 Target Audience: Primary-care physicians, emergency physicians, internists, and cardiologists. Keynotes: […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9170","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9170"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9170\/revisions"}],"predecessor-version":[{"id":9171,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9170\/revisions\/9171"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9170"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9170"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}